- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Telesis Bio Inc (TBIO)
OTC Markets
Currency in USD
0.0110
+0.0100(+1,000.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0110
0.0110
52 wk Range
0.0001
0.1500
TBIO Income Statement
Featured here, the Income Statement (earnings report) for Telesis Bio Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
| Period Ending: | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | 5.77 | 6.58 | 11.04 | 27.44 | 27.51 | |||||||||||||||||||||||||||||
Total Revenues Growth | - | +14.05% | +67.93% | +148.44% | +0.27% | |||||||||||||||||||||||||||||
Cost of Revenue | 3.21 | 2.95 | 6.74 | 11.84 | 10.56 | |||||||||||||||||||||||||||||
Gross Profit | 2.55 | 3.63 | 4.3 | 15.6 | 16.95 | |||||||||||||||||||||||||||||
Gross Profit Growth | - | +41.96% | +18.59% | +262.76% | +8.69% | |||||||||||||||||||||||||||||
Gross Profit Margin % | 44.29% | 55.12% | 38.93% | 56.84% | 61.62% | |||||||||||||||||||||||||||||
Other Operating Expenses, Total | 10.92 | 19.99 | 39.37 | 62.08 | 52.1 | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
Operating Income | -8.37 | -16.36 | -35.07 | -46.49 | -35.15 | |||||||||||||||||||||||||||||
Operating Income Growth | - | -95.44% | -114.38% | -32.53% | +24.38% | |||||||||||||||||||||||||||||
EBIT Margin % | -145.18% | -248.8% | -317.61% | -169.44% | -127.78% | |||||||||||||||||||||||||||||
Net Interest Expenses | -1.79 | -0.69 | -1.37 | -1.22 | -1.36 | |||||||||||||||||||||||||||||
Net Interest Expenses Growth | - | +61.41% | -98.41% | +11.1% | -11.91% | |||||||||||||||||||||||||||||
Interest Expense, Total | -1.79 | -0.69 | -1.37 | -1.96 | -3.11 | |||||||||||||||||||||||||||||
Interest And Investment Income | - | - | - | 0.74 | 1.74 | |||||||||||||||||||||||||||||
Other Non Operating Expenses, Total | 0.43 | -0.88 | -1.56 | -0.02 | 0.34 | |||||||||||||||||||||||||||||
EBT, Excl. Unusual Items | -9.73 | -17.93 | -38 | -47.72 | -36.18 | |||||||||||||||||||||||||||||
Gain (Loss) On Sale Of Assets | -0.23 | - | -0.03 | -0 | -0.14 | |||||||||||||||||||||||||||||
Other Unusual Items, Total | - | -0.07 | -0.62 | -0.73 | - | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items | -9.96 | -18.01 | -38.94 | -48.45 | -47.7 | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items Growth | - | -80.73% | -116.3% | -24.4% | +1.54% | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items Margin | -172.78% | -273.8% | -352.66% | -176.59% | -173.4% | |||||||||||||||||||||||||||||
Income Tax Expense | - | 0.01 | 0.01 | 0.02 | 0.02 | |||||||||||||||||||||||||||||
Net Income to Company | -9.96 | -18.01 | -38.96 | -48.47 | -47.72 | |||||||||||||||||||||||||||||
Minority Interest | - | - | - | - | - | |||||||||||||||||||||||||||||
Net Income | -9.96 | -18.01 | -38.96 | -48.47 | -47.72 | |||||||||||||||||||||||||||||
Net Income Growth | - | -80.78% | -116.31% | -24.42% | +1.54% | |||||||||||||||||||||||||||||
Net Income Margin % | -172.78% | -273.87% | -352.78% | -176.68% | -173.49% | |||||||||||||||||||||||||||||
Preferred Dividend and Other Adjustments | - | - | - | - | 1.3 | |||||||||||||||||||||||||||||
Net Income to Common Excl. Extra Items | -9.96 | -18.01 | -38.96 | -48.47 | -49.02 | |||||||||||||||||||||||||||||
Basic EPS - Continuing Operations | -35.86 | -64.82 | -38.48 | -29.61 | -29.56 | |||||||||||||||||||||||||||||
Basic EPS - Continuing Operations Growth | - | -80.72% | +40.63% | +23.05% | +0.17% | |||||||||||||||||||||||||||||
Diluted EPS - Continuing Operations | -35.86 | -64.82 | -38.48 | -29.61 | -29.56 | |||||||||||||||||||||||||||||
Diluted EPS - Continuing Operations Growth | - | -80.72% | +40.63% | +23.05% | +0.17% | |||||||||||||||||||||||||||||
Basic Weighted Average Shares Outstanding | 0.28 | 0.28 | 1.01 | 1.64 | 1.66 | |||||||||||||||||||||||||||||
Diluted Weighted Average Shares Outstanding | 0.28 | 0.28 | 1.01 | 1.64 | 1.66 | |||||||||||||||||||||||||||||
Dividend Per Share | - | - | - | - | - | |||||||||||||||||||||||||||||
Dividend Per Share Growth | - | - | - | - | - | |||||||||||||||||||||||||||||
EBITDA | -7.34 | -15.5 | -34.17 | -44.81 | -32.83 | |||||||||||||||||||||||||||||
EBITDA Growth | - | -111.02% | -120.5% | -31.17% | +26.74% | |||||||||||||||||||||||||||||
EBITDA Margin % | -127.35% | -235.63% | -309.39% | -163.35% | -119.34% | |||||||||||||||||||||||||||||
EBIT | -8.37 | -16.36 | -35.07 | -46.49 | -35.15 | |||||||||||||||||||||||||||||
* In Millions of USD (except for per share items)
FAQ
What was Telesis Bio’s revenue at year end?
At the end of the last reported fiscal year, Telesis Bio (TBIO) recorded total revenue of 27.5090 million USD.
How much revenue did Telesis Bio report in the most recent quarter?
In its most recent quarterly earnings report, Telesis Bio posted revenue of 1.5660 million USD.
What was Telesis Bio’s net income for the year?
For the full year, Telesis Bio reported net income of -47.7240 million USD.
How much net income did Telesis Bio post in the last quarter?
In the most recent quarter, Telesis Bio (TBIO) posted net income of -6.6420 million USD.
What was Telesis Bio’s gross profit for the year?
Gross profit for the year was reported at 16.9500 million USD.
How much gross profit did Telesis Bio generate last quarter?
Telesis Bio recorded gross profit of 1.0090 million USD in its latest quarterly report.
What was Telesis Bio’s annual operating income?
For the full year, Telesis Bio (TBIO) reported operating income of -35.1500 million USD.
What was Telesis Bio’s operating income last quarter?
Quarterly operating income was -5.1440 million USD.
What was Telesis Bio’s quarterly EBITDA?
In the latest quarter, EBITDA was reported at -4.6770 million USD.
What was the quarter-over-quarter change in EBITDA for Telesis Bio?
EBITDA changed by 53.4395% million USD compared to the last quarter.
What is Telesis Bio’s most recent gross profit margin?
The latest reported gross profit margin for Telesis Bio (TBIO) is 64.4316% million USD.
What is Telesis Bio’s most recent net income margin?
Net income margin based on recent financials is -424.1379% million USD.
What is Telesis Bio’s most recent EBIT margin?
Telesis Bio reported an EBIT margin of -328.4802% million USD based on current figures.
How did Telesis Bio’s revenue change compared to the previous quarter?
Revenue changed by 1.0323% million USD compared to the prior quarter.
What was the quarter-over-quarter change in gross profit for Telesis Bio?
In the latest quarter, gross profit changed by 226.2829% million USD from the previous quarter.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.